Epitomics INC. - production of blocking rabbit monoclonal antibody against human CD97.

Ended Purchase Order Awarded Last action

Contract number
HHSN261201600790P
Awardee
Awarding agency
Obligated
$35,865

Award facts

Opportunity
Contract value 100% obligated
$35,865.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Cambridge, MA 02139, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00001 · DE-obligation of funds from FY2016 expiring lines. -$4,434
Original award $40,299

About this award

The National Cancer Institute issued a purchase order to Epitomics Inc. for $35,865.00 on September 26, 2016, for production of blocking rabbit monoclonal antibody against human CD97. Work will be performed in Cambridge, Massachusetts. The order is firm fixed price with an ultimate completion date of September 25, 2017. No set-aside was used.

Quick answers

Who was awarded contract HHSN261201600790P?

HHSN261201600790P was awarded to Epitomics Inc. by National Cancer Institute (National Institutes of Health) on September 26, 2016.

How much is contract HHSN261201600790P worth?

The government has obligated $35,865 on HHSN261201600790P.

Was contract HHSN261201600790P competed?

The extent of competition for HHSN261201600790P was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award